The US FTC issues a FY 2017 report on branded drug firms’ patent settlements with generic competitors

FTC Staff Issues FY 2017 Report on Branded Drug Firms' Patent Settlements with Generic Competitors* The number of reverse-payment agreements remains low; for the first time since FY 2004, no agreement contains a no-AG commitment. According to a new FTC staff report, the total number of final Hatch-Waxman patent settlements entered by pharmaceutical companies in FY 2017 was close to the record high in FY 2016. Despite the high number of

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

Citation

US Federal Trade Commission, The US FTC issues a FY 2017 report on branded drug firms’ patent settlements with generic competitors, 3 décembre 2020, e-Competitions December 2020 - II, Art. N° 98294

Visites 111

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues